The authors would like to declare that the composition comprising KLK and ODN1a, an adjuvant used in the study was adapted from previous publications (ref. 30 and 31 in the paper) and does not represent the composition used by Intercell (owner of the intellectual property concerning IC31® and its uses) for their preclinical and clinical studies. Thus, for various regulatory and trademark concerns, as brought to our notice by Intercell, we would like to replace the term IC31® with the term “KLK/ODN1a composition” in our paper, i.e. IC31® should now read as “KLK/ODN1a composition”.


  1. Top of page
  2. References